Angiotensin induces inflammatory activation of human vascular smooth muscle cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 7, 1999, Pages 1623-1629

  Kranzhöfer, Roger ^a   Schmidt, Joachim ^a   Pfeiffer, Carolein A H ^a   Hagl, Siegfried ^a   Libby, Peter ^b   Kübler, Wolfgang ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiotensin; Atherosclerosis; Inflammation; Interleukins; Nuclear factor B; Smooth muscle

Indexed keywords

ANGIOTENSIN; CAPTOPRIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LOSARTAN; RAMIPRILAT;

ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; GROWTH REGULATION; HORMONAL REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOOTH MUSCLE FIBER; TRANSCRIPTION REGULATION; VASCULAR SMOOTH MUSCLE;

EID: 0033027919     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.7.1623     Document Type: Article

References (55)

1. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996;94:2756-2767.
2. Cambien F, Poirier O, Lecerf L, Evans A, Cambou J, Arveiler D, Luc G, Bard J, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359: 641-644.
3. Katsuya T, Koike G, Yee TW, Sharpe N, Jackson R, Norton R, Horiuchi M, Pratt RE, Dzau VJ, MacMahon S. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet. 1995;345:1600-1603.
4. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, Buring J, Hennekens CH. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemie heart disease. N Engl J Med. 1995;332:706-711.
5. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324: 1098-1104.
6. Meade TW, Cooper JA, Pearf WS. Plasma renin activity and ischemic heart disease. N Engl J Med. 1993;329:616-619.
7. Alderman MH, Ooi WL, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. J Hypertens. 1997;10:1-8.
8. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
9. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejections fractions. N Engl J Med. 1992;327:685-691.
10. Rutherford JD, Pfeffer MA, Moyé LA, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Rouleau JL, Braunwald E. Effects of captopril on ischemic events after myocardial infarction: results of the survival and ventricular enlargement trial. Circulation. 1994;90: 1731-1738.
11. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15:327-331.
12. Campbell-Boswell M, Robertson AL. Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. Exp Mol Pathol. 1981; 35:265-276.
13. Geisterfer AAT, Peach MJ, Owens GK. Angiotensin induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988;62:749-756.
14. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth-factor A chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1419-1424.
15. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest. 1993;91:2268-2274.
16. Munro JM, Cotran RS. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest. 1988;58:249-261.
17. Alexander RW. Inflammation and coronary artery disease. N Engl J Med. 1994;331:468-469.
18. Clinton SK, Libby P. Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med. 1992;116:1292-1300.
19. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995;25(suppl 2):S9-S12.
20. Warner SJC, Auger KR, Libby P. Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells. J Exp Med. 1987;165:1316-1331.
21. Warner SJC, Libby P. Human vascular smooth muscle cells: target for and source of tumor necrosis factor. J Immunol. 1989;142:100-109.
22. Loppnow H, Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest. 1990;85:731-738.
23. Wang JM, Sica A, Peri G, Walter S, Padura IM, Libby P, Ceska M, Lindley I, Colotta F, Mamovani A. Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb. 1991;11:1166-1174.
24. Clinton SK, Underwood R, Hayes L, Sherman ML, Kufe DW, Libby P. Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol. 1992;140: 301-316.
25. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified LDL induces monocyte chemotactic protein 1 in human endothelial and smooth muscle cells. Proc Natl Acad Sci USA. 1990;87:5134-5138.
26. Kranzhöfer R, Clinton SK, Ishii K, Coughlin SR, Fenton JW II, Libby P. Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes. Circ Res. 1996; 79:286-294.
27. Le JM, Vilcek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest. 1989;61:588-602.
28. Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol. 1991;97:686-692.
29. Tsukada T, McNutt MA, Ross R, Gown AM. HHF35, a muscle actin-specific monoclonal antibody. II. Reactivity in normal, reactive, and neoplastic human tissues. Am J Pathol. 1987;127:389-402.
30. Libby P, O'Brien KV. Culture of quiescent arterial smooth muscle cells in a defined serum-free medium. J Cell Physiol. 1983;115:217-223.
31. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997;80:219-227.
32. Schreck R, Rieber P, Baüerle PA. Reactive oxygen intermediates as widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J. 1991;10:2247-2258.
33. Satriano JA, Shuldiner M, Hora K, Xing Y, Schlondorff D. Oxygen radicals as second messengers for expression of the monocyte chemoattractant protein. JE/MCP-1, and the monocyte colony-stimulating factor, CSF-1, in response to tumor necrosis factor-a and immunoglobulin G. J Clin Invest. 1993;92:1564-1571.
34. 1 expression determines growth response to angiotensin II. J Clin Invest. 1992;90: 456-461.
35. Kato H, Suzuki H, Tajima S, Ogata Y, Tominaga T, Sat A, Saruta T. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens. 1991;9:17-22.
36. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest. 1995;95:1353-1362.
37. Hernández-Presa M, Bustos C, Ortego M, Tuñon J, Renedo G, Ruiz-Ortega M, Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997;95:1532-1541.
38. Moriyama T, Fujibayashi M, Fujiwara Y, Kaneko T, Xia C, Imai E, Kamada T, Ando A, Ueda N. Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells. J Am Soc Nephrol. 1995; 6:95-101.
39. Hahn AWA, Jonas U, Bühler FR, Resink TJ. Activation of human peripheral monocytes by angiotensin II. FEBS Lett. 1994;347:178-180.
40. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA Jr. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA. 1987;84:9238-9242.
41. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
42. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, Maseri A. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996;94:874-877.
43. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol. 1989;135:169-175.
44. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44.
45. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
46. Zhang X, Scicli GA, Xu X, Nasjletti A, Hintze TH. Role of endothelial kinins in control of coronary nitric oxide production. Hypertension. 1997; 30:1105-1111.
47. Shin WS, Hong Y-H, Peng H-B, De Caterina R, Libby P, Liao JK. Nitric oxide attenuates vascular smooth muscle cell activation by interferon-γ. J Biol Chem. 1996;271:11317-11324.
48. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Imnnmol. 1994;12:141-179.
49. Liberman TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol. 1990;10: 2327-2334.
50. Brand K, Page S, Rogler G, Bartsch A, Brandi R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Iinvest. 1996;97:1715-1722.
51. Bourcier T, Sukhova G, Libby P. The nuclear factor κ-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem. 1997;272:15817-15824.
52. Collins T. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab Invent. 1993;68:499-508.
53. Griendling KK, Tsuda T, Berk BC, Alexander RW. Angiotensin II stimulation of vascular smooth muscle cells: secondary signalling mechanisms. Am J Hypertens. 1989;2:659-665.
54. Schieffer B, Wyrwoll F, Brauer N, Drexler H. Angiotensin II enhances the expression and release of interleukin-6 in human coronary smooth muscle cells: involvement of the Jak/Stat pathway. Circulation. 1997; 96(suppl I):I-415. Abstract.
55. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.